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Objectives: To determine whether topical fibrin sealant reduced suture line bleeding during carotid endarterectomy with 
polytetrafluoroethylene (PTFE) patch closure. 
Desfgm Prospective randomised non-blinded control trial. 
Setting.. Regional vascular surgery unit. 
Materials: Seventeen patients undergoing carotid endarterectomy were randomised either to receive fibrin sealant as a 
topical haemostatic agent at the arteriotomy suture line or to act as control. 
Outcome measures: Time taken to achieve haemostasis at the suture line. Intraoperative blood loss. Total operative 
time. 
Results: The median time to achieve haemostasis was 5.5 min (range 4-31 rain) in the treatment group and 19 min (range 
10--47 min) in the control group. This difference was statistically significant p < 0.005 by Mann-Whitney test. There was 
no statistical difference in total operative time. Operative blood loss was lower in the treatment group (median 420mi, range 
300-500mi) than in the control group (median 550mi, range 350-1200mi) but this difference was not statistically 
significant. One patient in the control group suffered aperioperative thrombo-embolic event. 
ConcluMon: Fibrin sealant is an effective topical haemostatic agent for arteriotomy suture lines involving PTFE 
material. 
Key Words: Randomised controlled trial; Polytetrafluoroethylene; Carotid surgery; Fibrin sealant; Haemostasis. 
Introduction 
Suture line bleeding at vascular anastomoses i a 
problem which can increase operative blood loss and 
lengthen operating time. This is especially a problem 
in anastomoses involving polytetrafluoroethylene 
(PTFE) grafts and patches and may be exacerbated by 
the use of intraoperative heparin. 
Fibrin sealant is a topical haemostatic agent which 
consists of two principal components, fibrinogen and 
thrombin, which are mixed, in the presence of Factors 
VIII and XIII, fibronectin and calcium to produce 
insoluble fibrin. Thus the main components of the 
final stage in the physiological pathway of coagulation 
are present. 
Fibrin sealant of this form was first described in 
1972 as a tissue adhesive for nerve repair. 1Since then 
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it has been used in a wide variety of clinical settings: 
otolaryngolog~ 2 plastic surger~ 3"4 neurosurger~ ~-7 
8 12 1314 thoracic surgery, - hepatobiliary surgery, ' pancre- 
atic surger~ 15"16 colorectal surgery, ~7 gynaecology 18"19 
and cardiac surgery. 2°-26 
The possibilities for using fibrin sealant in cardio- 
vascular surgery were recognised by Spangler early 
on during its development. 27 Borst and Haverich 
(1982) further developed and promoted the use of 
fibrin sealant in this field describing its use for sealing 
knitted Dacron aortic grafts, puncture holes and 
suture lines in vascular anastomoses. 2°'2~ 
The success of fibrin sealant in cardiac surgery 
would suggest hat it may also be useful in peripheral 
vascular surgery. However there have been few 
studies of fibrin sealant in this setting. In randomised 
trials using an animal model of peripheral vascular 
surgery with PTFE grafts, fibrin sealant was shown to 
be more effective than oxidised regenerated cellulose 
in controlling anastomotic bleeding. 28'29 However 
there are no reports of the clinical use of fibrin sealant 
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in peripheral vascular surgery. Carotid endarter- 
ectomy using a PTFE patch is associated with pro- 
longed anastomotic bleeding and the aim of this study 
was to determine whether fibrin sealant could sig- 
nificantly reduce suture line bleeding in these 
patients. 
Material and Methods 
The study was a prospective, randomised non-blinded 
trial. An initial pilot study involving eight patients 
was carried out in order to familiarise surgeons and 
theatre staff with the use of fibrin sealant prior to the 
commencement of the trial. 
Patients and operative details 
Patients were recruited from the vascular surgery unit 
of the Royal Infirmary of Edinburgh. All patients gave 
informed written consent and the trial was approved 
by the local ethical committee. Past medical history 
and drug use within the previous 14 days was 
recorded. To allow assessment of the viral safety of the 
sealant (as part of a larger safety study) patients who 
were known to be seropositive for anti-HIV, who had 
a history of hepatitis or whose liver function tests were 
outside the normal range were excluded. In addition, 
patients with a history of severe reactions to blood 
products or concurrent disease which might com- 
promise their ability to be retained within the study 
were also excluded. A venous blood sample was taken 
for haemoglobin, haematocrit, platelet and white cell 
count, prothrombin time, activated partial thrombo- 
plastin time and liver function tests. A serum sample 
was stored at -40°C for later viral studies if 
required. 
The mean age of patients was 64.5 years (range 
48-75 years) and there was no difference in mean age 
between the patients in the treatment and control 
groups. Fifteen patients were taking regular aspirin; 
both the patients not taking aspirin were in the control 
group. No patient had any abnormality on pre- 
operative coagulation screen. 
Following entry into the trial the patients were 
randomised in a computer-generated sequence to 
treatment or control groups. In the treatment group, 
following completion of the vascular anastomosis, 
fibrin sealant was applied to the suture line using a 
dual syringe technique. B°In the control group nothing 
was applied to the suture line. The clamps were 
released 2 min after application was complete. Pres- 
sure was applied with surgical swabs if there was 
significant bleeding. The surgeon was allowed to use 
haemostatic gauze at any time. The arteriotomy was 
inspected frequently and the time taken to achieve 
haemostasis from release of the clamps was 
recorded. 
Surgical treatment was otherwise identical in the 
two groups. All operations were performed under 
general anaesthetic with subcutaneous local anaes- 
thetic infiltration. The operations were all performed 
(6/9 control; 5/8 treatment) or supervised by one 
surgeon (C.V.R.). All patients received intraoperative 
heparin, 5000 I.U. before the artery was clamped. The 
heparin was not reversed. Arteriotomy closure was 
performed using a 0.5 mm PTFE patch (WL Gore) and 
7.0 Goretex suture. In both groups any further 
manoeuvres, uch as application of pressure or hae- 
mostatic gauze, required to achieve haemostasis were 
recorded. The length of operation, blood product 
usage were recorded and a personal assessment by the 
surgeon of effectiveness and ease of use was also 
recorded. 
Patients were followed-up for 26 weeks. Blood was 
taken at 24 h and 5 days for haemoglobin, haematocrit, 
platelet count and white cell count; at 6 weeks and 12 
weeks for liver function tests and at 26 weeks for 
virology testing. Virology testing consisted of deter- 
mining the presence of hepatitis B surface antigen and 
enzyme immunoassay for antibodies to hepatitis A 
and hepatitis C, bioluminescence assay for antibodies 
to hepatitis B surface antigen, and radioimmunoassay 
for antibodies to hepatitis B core antigen. 
Fibrin sealant kit was provided for the study by the 
Scottish National Blood Transfusion Service (SNBTS). 
Heat-treated human fibrinogen was manufactured at
the SNBTS Protein Fractionation Centre from pooled 
donor plasma cryosupernatant. Solvent detergent 
treated human thrombin preparation was supplied by 
the Centre Regional de Transfusion Sanguine (CRTS) 
(Lille, France). The fibrin sealant supplied by SNBTS 
uses concentrations of thrombin between 200-500 
I.U./ml and fibrinogen 29-39g/1. 31 
After 17 patients had been randomised it appeared 
to the surgeon and anaesthetist that there was a 
clinical benefit in patients treated with fibrin sealant 
and an interim analysis of the data was requested. 
This confirmed that there was a statistically significant 
benefit and the trial was stopped. Statistical analysis 
was carried out using a Mann-Whitney U test. 
Results 
The median time to achieve haemostasis was 5.5 min 
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(range 4-31 min) in the treatment group and 19 min 
(range 10-47 min) in the control group (Fig. 1). This 
difference was statistically significant p<0.005 by 
Mann-Whitney test. There was no statistical difference 
in total operative time. Operative blood loss was 
lower in the treatment group (median:420ml, 
range:300-500ml) than in the control group (median 
550ml, range 350-1200ml) but this difference was not 
statistically significant. All patients (9/9) in the control 
group and one patient (1/8) in the fibrin sealant group 
required the use of oxidised cellulose gauze to aid 
haemostasis. In no cases were further sutures required 
to achieve haemostasis. There were no significant 
differences in the drop in haemoglobin following 
operation. There was no serological evidence of 
hepatitis A, B or hepatitis C transmission at 6 months 
and no patients developed abnormal liver function 
tests during follow-up. 
One patient in the control group suffered a post- 
operative cerebrovascular ccident on the ipsilateral 
side to operation. There was no evidence of arterial 
embolism or thrombosis in the treatment group. No 
patients required reoperation for control of haemor- 
rhage or evacuation of haematoma. There were no 
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Fig. 1. Time to achieve haemostasis in carotid endarterectomy. 
Discussion 
This study has shown that fibrin sealafit is an effective 
topical haemostatic agent in vascular surgery. The 
only statistically significant benefit was a shorter time 
to achieve haemostasis. Blood loss was lower in the 
treatment group but this did not attain statistical 
benefit. This may be a type II statistical error: the trial 
was terminated after interim analysis was requested 
by the surgical team to confirm a clinical impression of 
haemostatic effectiveness. 
It may be expected that fibrin-based adhesives and 
sealants are likely to be useful agents for surgical 
haemostasis and tissue adhesion since fibrin plays a 
central role in the physiological process of wound 
healing. Thus problems of foreign body reaction, 
delayed healing and fibrosis, which are associated 
with other haemostatic agents, might be avoided. The 
major advantages of fibrin-based glues over other 
tissue adhesives are tissue compatibility, biodegrad- 
ability and the ability to adhere to wet surfaces. It may 
even promote healing since the first stage in normal 
wound healing is the production of a fibrin network 
into which fibroblasts and capillaries migrate. Evi- 
dence in support of this has been derived from several 
animal s tud ies .  28"29'31-34 
Concern has been expressed that viral transmission 
could occur as a result of fibrin sealant use. Theoret- 
ically virus remaining in the preparation could be 
adsorbed and retained by the patient and there are 
reports in the literature which implicate cryoprecipi- 
tated fibrinogen as a mechanism for the transmission 
of HIV-1 and hepatitis. 35'36 Therefore the method of 
production has been designed to minimise the risk of 
viral transmission. The safety of fibrin sealant is 
further supported by this study in which no evidence 
of viral transmission could be found. The study of 
viral safety of this product is continuing, involving 
approximately 100 patients in detailed follow-up. 
A further concern over the use of fibrin sealant on 
arterial suture lines is that it may promote intra- 
vascular thrombosis or embolism. No evidence to 
support such concerns was found in this study or has 
been reported elsewhere. There was only one embolic 
event and that was in a patient in the control group. 
This study demonstrates that fibrin sealant is an 
effective and safe haemostatic agent for vascular 
suture lines involving PTFE. 
Acknowledgements 
We are grateful to Dr R. Prescott for the statistical analysis. The 
authors would also like to acknowledge the assistance of the theatre 
Eur J Vasc Endovasc Surg Vol 10, July 1995 
94 A.A. Milne et aL 
staff in the vascular unit in the Royal Infirmary of Edinburgh. A.A. 
Milne is supported by a research grant of the SNBTS. 
References 
1 MATRAS H, DINGES H, LASSMAN H, MAMMOLI B. Zur nahtlosen 
interfaszikularen erventransplantation im tierexperiment. 
(Suture-free interfascicular nerve transplantation i  animal 
experiments). Wien Med Wochenshr 1972; 122: 517-523. 
2 STAINDL O. Tissue adhesion with highly concentrated human 
fibrinogen in otolaryngology. Ann Otol 1979; 88: 413-418. 
3 MARCHAC D, RENIER D. Fibrin glue in craniofacial surgery. J
Craniofacial Surg 1990; 1: 32-34. 
4 VOBEL A, O'GRADY K, TORIUMI DM. Surgical tissue adhesives in 
facial plastic and reconstructive surgery. Facial Plastic Surg 1993; 
9: 49-57. 
5 POMERANZ S, CONSTANTINI S, UMANSKY F. The use of fibrin sealant 
in cerebrospinal fluid leakage. Neurochirurgfa 1991; 34: 166-169. 
6 LEE KC, PARK SK, LEE KS. Neurosurgical application of fibrin 
adhesive. Yonsei Med J 1991; 32: 53-57. 
7 CaIN JE, DRYER RE, BARTON BR. Evaluation of dural closure 
techniques. Suture methods, fibrin adhesive sealant and cyanoa- 
crylate polymer. Spine 1988; 13: 720-725. 
8 MOURITZEN C, DROMER M, KEINECKE HO. The effect of fibrin 
glueing to seal bronchial and alveolar leakages after pulmonary 
resections and decortications. Eur J Cardio-Thorac Surg 1993; 7: 
75-80. 
9 THETTER O. Fibrin adhesive and its application in thoracic 
surgery. Thorac Cardiovasc Surg 1981; 29: 290. 
10 McCARTHY PM, TRASTEK VII BELL DG et al. The effectiveness of
fibrin glue for reducing experimental pulmonary air leak. Ann 
Thorac Surg 1988; 45: 203-205. 
11 GOLDMAN CD, BLOCKER SH, TERNBERG JL, CROUCH EC. Manage- 
ment of experimental pneumothorax in weanling rabbits with 
the use of fibrin glue sclerosant. Arch Surg 1986; 121: 565-568. 
12 JESSEN C~ SHARMA P. Use of fibrin glue in thoracic surgery. Ann 
Thorac Surg 1985; 39: 521-524. 
13 CHISHOLM RA, JONES SN, LEES WR. Fibrin sealant as a plug for the 
post liver biopsy needle track. Clin RadioI 1989; 40: 627-628. 
14 KOHNO H, NAGASUE N, CHANG YC, TANIURA H, YAMANOI A, 
NAKAMURA T. Comparison of topical haemostatic agents in 
elective hepatic resection: a clinical prospective randomized 
trial. World ] Surg 1992; 16: 966-969. 
15 MARCZELL AP, STIERER M. Partial pancreatiocoduodenectomy 
(Whipple procedure) for pancreatic malignancy: occlusion of a 
non-anastomosed pancreatic stump with fibrin sealant. HPB 
Surg 1992; 5: 251-259. 
16 KRAM HB, CLARK SR, OCAMPO HP, YAMAGUCHI MA, SHOEMAKER 
WC. Fibrin glue sealing of pancreatic injuries, resections and 
anastomoses. Am J Surg 1991; 161: 479-481. 
17 HJORTUP A, MOESGAARD Fy KJAERGARD J. Fibrin adhesive on the 
treatment of perineal fistulas. Dis Colon Rectum 1991; 34: 
752-754. 
18 FEICHTINGER W, BARAD D, FEINMAN M, BARG P. The use of fibrin 
sealant for embryo transfer. Fertil Steril 1990; 54: 733-734. 
19 ADAMYAN LV, MYLNBAYEV OA, KULAKOV VI. Use of fibrin glue in 
obstetrics and gynaecology: a review of the literature. Int J Fertil 
1991; 36: 81-88. 
20 BORST HG, HAVERICH A, WALTERBUSCH G, MAATZ W. Fibrin 
adhesive: An important hemostatic adjunct in cardiovascular 
operations. J Thorac Cardiovasc Surg 1982; 84: 548-553. 
21 BORST HG, HAVERICH A. Fibrin seal in cardiovascular surgery. 
Proceedings of a workshop. Thorac Cardiovasc Surg 1982; 30: 
195-224. 
22 Rousou J, GONZALEZ-LAVIN L, COSGROVE D et aI. Randomized 
clinical trial of fibrin sealant in patients undergoing rest- 
ernotomy or reoperation after cardiac operations. J Thorac 
Cardiovasc Surg 1989; 97: 194-203. 
23 Rousou JA, ENGELMAN R_]V[, BREYER RH. Fibrin glue: an effective 
hemostatic agent for non-suturable intraoperative bleeding. Ann 
Thorac 8urg 1984; 38: 409410. 
24 SPONITZ WW, DALTON MS, BAKER JW, NOLAN SP. Reduction of 
perioperative h morrhage by anterior mediastinal spray applica- 
tion of fibrin glue during cardiac operations. Ann 7Fhorac Surg 
1987; 44: 529-531. 
25 SECLaN JR, FRAPIER J-M, COLSON P, CHAPTAL P. Fibrin sealant 
improves urgical results of type A acute aortic dissections. Ann 
Thorac Surg 1991; 52: 745-749. 
26 STARK J, DE LEVAL M. Experience with Fibrin Seal (Tisseel) in 
operations for congenital heart defects. Ann Thorac Surg 1984; 38: 
411-413. 
27 SPANGLER H. Gewebeldebung und lokale blutstillung mit fibrino- 
gen, thrombin und blutgerinnungsfaktor XIII. Wien Klin 
Wochenschr 1976; 88 (suppl 49): 1-18. 
28 KRAM H, NUGENT P, REUBEN B, SHOEMAKER W. Fibrin glue sealing 
of polytetrofluoroethylene vascular graft anastamoses: compar- 
ison with oxidosed cellulose. J Vasc Surg 1988; 8: 563-568. 
29 JAKOB H, CAMPBELL Ci Qtn Z, PICK I~ REPOGLE R. Use of fibrin 
sealant for reinforcing arterial anastomoses. I Vasc Surg 1984; 1: 
171-179. 
30 MATRAS H. Fibrin seal: the state of the art. J Oral Maxillofac Surg 
1985; 43: 605-611. 
31 BYRNE D, HARDY J, WOOD R, MCINTOSH R, CISCHIERI A. Effect of 
fibrin glues on the mechanical properties of healing wounds. Br 
] Surg 1991; 78: 841443. 
32 HARRIS DM, SIEDENTOP KH, HAM KR, SANCHEZ B. Autologous 
fibrin tissue adhesive biodegradation and systemic effects. 
Laryngoscope 1987; 97: 1141-1144. 
33 JONAS R, SCHOEN F, ZIEMER G, BRITTON L, CASTANEDA A. Biological 
sealants and knitted dacron conduits: Comparison of collagen 
and fibrin glue pretreatments in circulatory models. Ann Thorac 
Surg 1987; 44: 283-290. 
34 JONAS R, SCHOEN F / LEVY R, CASTANEDA A. Biological sealants and 
knitted dacron: porosity and histological comparisons of vas- 
cular graft materials with and without collagen and fibrin glue 
pretreatments. Ann Thorac Surg 1986; 41: 657-663. 
35 WILSON SM, PELL P, DONEGAN EA. HIV-1 transmission following 
the use of cryoprecipitated fibrinogen as a gel/adhesive. 
Transfusion 1991; 31: 515. 
36 BovE JR. Fibrinogen - -  Is it worth the risk? Transfusion 1978; 19: 
129-136. 
Accepted 8 December 1994 
Eur J Vasc Endovasc Surg Vol 10, July 1995 
